{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:01:25Z","timestamp":1771326085452,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>6-Thioguanine is an immunosuppressive drug, an analogue of guanine, applied to treat acute leukemia and inflammatory bowel disease. Excessive use of 6-thioguanine during clinical treatment may cause side effects. Moreover, providing a dose too low will be ineffective. Therefore, there is a critical need for a rapid, selective and routine approach to quantifying 6-thioguanine in body fluids to support a clinical application. A fully validated HPLC method has been developed to determine 6-thioguanine in whole blood samples using 5-bromouracil as an internal standard. 6-Thioguanine nucleotides were released from erythrocytes by perchloric acid, and then hydrolysed at 100\u00a0\u00b0C to the parent thiopurine, 6-thioguanine. The following validation parameters of the method were determined: specificity\/selectivity, linearity range (479\u201317,118\u00a0ng\/mL, R\u2009&gt;\u20090.992), limits of detection (150\u00a0ng\/mL) and quantification (479\u00a0ng\/mL), accuracy (\u2212\u20095.6\u2009&lt;\u2009Bias\u2009&lt;\u200914.7), repeatability (CV 1.30\u20133.24%), intermediate precision (CV 4.19\u20135.78%), extraction recovery (79.1\u2013103.6%) and carryover. Furthermore, the stability of the drug in whole blood samples under various storage conditions was investigated. The suggested method is suitable for determining 6-thioguanine in whole blood erythrocyte samples for drug level monitoring, thus correct dosing.<\/jats:p>","DOI":"10.1038\/s41598-023-41426-5","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T18:04:36Z","timestamp":1693332276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of innovative methodology for determination of 6-thioguanine in whole blood erythrocytes by HPLC\u2013PDA-based technique for medical diagnostics purposes"],"prefix":"10.1038","volume":"13","author":[{"given":"Maciej","family":"Noga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Zakrzewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Wianowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Gnatowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Paprotny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamil","family":"Jurowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"41426_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.tiv.2007.12.004","volume":"22","author":"E Petit","year":"2008","unstructured":"Petit, E. et al. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol. In Vitro 22, 632\u2013642 (2008).","journal-title":"Toxicol. In Vitro"},{"key":"41426_CR2","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N. Engl. J. Med. 362, 1383\u20131395 (2010).","journal-title":"N. Engl. J. Med."},{"key":"41426_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1053\/j.gastro.2018.08.043","volume":"156","author":"SB Hanauer","year":"2019","unstructured":"Hanauer, S. B., Sandborn, W. J. & Lichtenstein, G. R. Evolving considerations for thiopurine therapy for inflammatory bowel diseases\u2014A clinical practice update: Commentary. Gastroenterology 156, 36\u201342 (2019).","journal-title":"Gastroenterology"},{"key":"41426_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1111\/j.1572-0241.2007.01530.x","volume":"102","author":"A Ferlitsch","year":"2007","unstructured":"Ferlitsch, A. et al. 6-Thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am. J. Gastroenterol. 102, 2495\u20132503 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"41426_CR5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1542-3565(04)00344-1","volume":"2","author":"MC Dubinsky","year":"2004","unstructured":"Dubinsky, M. C. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety. Clin. Gastroenterol. Hepatol. 2, 731\u2013743 (2004).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"41426_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bios.2015.03.001","volume":"70","author":"T-P Huynh","year":"2015","unstructured":"Huynh, T.-P. et al. Cytosine derivatized bis(2,2\u2032-bithienyl)methane molecularly imprinted polymer for selective recognition of 6-thioguanine, an antitumor drug. Biosens. Bioelectron. 70, 153\u2013160 (2015).","journal-title":"Biosens. Bioelectron."},{"key":"41426_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/pds.3621","volume":"23","author":"F Beigel","year":"2014","unstructured":"Beigel, F. et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies: Malignancy risk in ibd treatment. Pharmacoepidemiol. Drug Saf. 23, 735\u2013744 (2014).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"41426_CR8","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre, M. et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 318, 1679 (2017).","journal-title":"JAMA"},{"key":"41426_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bbrc.2013.06.067","volume":"437","author":"H Karim","year":"2013","unstructured":"Karim, H., Ghalali, A., Lafolie, P., Vitols, S. & Fotoohi, A. K. Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells. Biochem. Biophys. Res. Commun. 437, 280\u2013286 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"41426_CR10","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1097\/MIB.0000000000000122","volume":"20","author":"G Marinkovi\u0107","year":"2014","unstructured":"Marinkovi\u0107, G., Hamers, A. A. J., de Vries, C. J. M. & de Waard, V. 6-Mercaptopurine reduces macrophage activation and gut epithelium proliferation through inhibition of GTPase Rac1. Inflamm. Bowel Dis 20, 1487\u20131495 (2014).","journal-title":"Inflamm. Bowel Dis"},{"key":"41426_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/clinchem\/48.1.61","volume":"48","author":"T Dervieux","year":"2002","unstructured":"Dervieux, T. et al. HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clin. Chem. 48, 61\u201368 (2002).","journal-title":"Clin. Chem."},{"key":"41426_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/FTD.0b013e31826ec4b4","volume":"34","author":"M Misdaq","year":"2012","unstructured":"Misdaq, M., Andag, R., Oellerich, M., Asif, A. R. & von Ahsen, N. Establishment of thiopurine S-methyltransferase gene knockdown in Jurkat T-lymphocytes: An in vitro model of TPMT polymorphism. Ther. Drug Monit. 34, 584\u2013592 (2012).","journal-title":"Ther. Drug Monit."},{"key":"41426_CR13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1258\/000456306778520070","volume":"43","author":"L Ford","year":"2006","unstructured":"Ford, L., Graham, V. & Berg, J. Whole-blood thiopurine S-methyltransferase activity with genotype concordance: a new, simplified phenotyping assay. Ann. Clin. Biochem. 43, 354\u2013360 (2006).","journal-title":"Ann. Clin. Biochem."},{"key":"41426_CR14","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1136\/gut.48.5.642","volume":"48","author":"C Cuffari","year":"2001","unstructured":"Cuffari, C., Hunt, S. & Bayless, T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48, 642\u2013646 (2001).","journal-title":"Gut"},{"key":"41426_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/clpt.2010.320","volume":"89","author":"M Relling","year":"2011","unstructured":"Relling, M. et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89, 387\u2013391 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"41426_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0009-9236(97)90152-1","volume":"62","author":"D Otterness","year":"1997","unstructured":"Otterness, D. et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin. Pharmacol. Ther. 62, 60\u201373 (1997).","journal-title":"Clin. Pharmacol. Ther."},{"key":"41426_CR17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2217\/pgs.14.32","volume":"15","author":"L Chouchana","year":"2014","unstructured":"Chouchana, L. et al. Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring. Pharmacogenomics 15, 745\u2013757 (2014).","journal-title":"Pharmacogenomics"},{"key":"41426_CR18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.cgh.2014.12.026","volume":"13","author":"AJ Yarur","year":"2015","unstructured":"Yarur, A. J. et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin. Gastroenterol. Hepatol. 13, 1118-1124.e3 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"41426_CR19","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","volume":"118","author":"MC Dubinsky","year":"2000","unstructured":"Dubinsky, M. C. et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118, 705\u2013713 (2000).","journal-title":"Gastroenterology"},{"key":"41426_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.crohns.2009.02.002","volume":"3","author":"WGN Mares","year":"2009","unstructured":"Mares, W. G. N. et al. Safe 6-thioguanine therapy of a TPMT deficient Crohn\u2019s disease patient by using therapeutic drug monitoring. J Crohn\u2019s Colitis 3, 128\u2013130 (2009).","journal-title":"J Crohn\u2019s Colitis"},{"key":"41426_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.dld.2006.10.007","volume":"39","author":"LPL Gilissen","year":"2007","unstructured":"Gilissen, L. P. L. et al. Toxicity of 6-thioguanine: No hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine: Some evidence for dose or metabolite level dependent effects?. Dig. Liver Dis. 39, 156\u2013159 (2007).","journal-title":"Dig. Liver Dis."},{"key":"41426_CR22","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1007\/s00216-019-01868-1","volume":"411","author":"B Friedl","year":"2019","unstructured":"Friedl, B., Kurlbaum, M., Kroiss, M., Fassnacht, M. & Scherf-Clavel, O. A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring. Anal. Bioanal. Chem. 411, 3951\u20133962 (2019).","journal-title":"Anal. Bioanal. Chem."},{"key":"41426_CR23","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00216-011-5304-9","volume":"401","author":"T Tachi","year":"2011","unstructured":"Tachi, T. et al. A clinical trial for therapeutic drug monitoring using microchip-based fluorescence polarization immunoassay. Anal. Bioanal. Chem. 401, 2301\u20132305 (2011).","journal-title":"Anal. Bioanal. Chem."},{"key":"41426_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jpba.2014.05.040","volume":"98","author":"A De Nicol\u00f2","year":"2014","unstructured":"De Nicol\u00f2, A. et al. UPLC\u2013MS\/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. J. Pharm. Biomed. Anal. 98, 271\u2013278 (2014).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"41426_CR25","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1021\/ac2031699","volume":"84","author":"U Hofmann","year":"2012","unstructured":"Hofmann, U. et al. Simultaneous quantification of eleven thiopurine nucleotides by liquid chromatography-tandem mass spectrometry. Anal. Chem. 84, 1294\u20131301 (2012).","journal-title":"Anal. Chem."},{"key":"41426_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/FTD.0b013e318283ed5d","volume":"35","author":"H Kirchherr","year":"2013","unstructured":"Kirchherr, H., Shipkova, M. & von Ahsen, N. Improved method for therapeutic drug monitoring of 6-thioguanine nucleotides and 6-methylmercaptopurine in whole-blood by LC\/MSMS using isotope-labeled internal standards. Ther. Drug Monit. 35, 313\u2013321 (2013).","journal-title":"Ther. Drug Monit."},{"key":"41426_CR27","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1373\/clinchem.2005.050831","volume":"51","author":"T Dervieux","year":"2005","unstructured":"Dervieux, T. et al. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine\/6-mercaptopurine therapy. Clin. Chem. 51, 2074\u20132084 (2005).","journal-title":"Clin. Chem."},{"key":"41426_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-4347(00)00513-2","volume":"757","author":"MG Pike","year":"2001","unstructured":"Pike, M. G. et al. Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J. Chromatogr. B Biomed. Sci. Appl. 757, 1\u20139 (2001).","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"41426_CR29","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1139\/y96-056","volume":"74","author":"C Cuffari","year":"1996","unstructured":"Cuffari, C., Seidman, E. G., Latour, S. & Th\u00e9or\u00eat, Y. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn\u2019s disease patients on maintenance 6-mercaptopurine therapy. Can. J. Physiol. Pharmacol. 74, 580\u2013585 (1996).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"41426_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jpba.2012.11.027","volume":"75","author":"S Vikingsson","year":"2013","unstructured":"Vikingsson, S., Almer, S., Peterson, C., Carlsson, B. & Josefsson, M. Monitoring of thiopurine metabolites: A high-performance liquid chromatography method for clinical use. J. Pharm. Biomed. Anal. 75, 145\u2013152 (2013).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"41426_CR31","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1177\/039463201202500213","volume":"25","author":"G Cangemi","year":"2012","unstructured":"Cangemi, G. et al. A validated HPLC method for the monitoring of thiopurine metabolites in whole blood in paediatric patients with inflammatory bowel disease. Int. J. Immunopathol. Pharmacol. 25, 435\u2013444 (2012).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"41426_CR32","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3390\/metabo12121173","volume":"12","author":"M Franzin","year":"2022","unstructured":"Franzin, M. et al. A validated HPLC\u2013diode array detection method for therapeutic drug monitoring of thiopurines in pediatric patients: From bench to bedside. Metabolites 12, 1173 (2022).","journal-title":"Metabolites"},{"key":"41426_CR33","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinbiochem.2004.05.025","volume":"37","author":"C Stefan","year":"2004","unstructured":"Stefan, C., Walsh, W., Banka, T., Adeli, K. & Verjee, Z. Improved HPLC methodology for monitoring thiopurine metabolites in patients on thiopurine therapy. Clin. Biochem. 37, 764\u2013771 (2004).","journal-title":"Clin. Biochem."},{"key":"41426_CR34","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation (2011)."},{"key":"41426_CR35","unstructured":"ICH. Final endorsed concept paper. M10: Bioanalytical method validation. EU guideline bioanalytical method validation. (2016)."},{"key":"41426_CR36","unstructured":"ISO\/IEC 17025. General requirements for the competence of testing and calibration laboratories. (2005)."},{"key":"41426_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jps.2600810324","volume":"81","author":"VP Shah","year":"1992","unstructured":"Shah, V. P. et al. Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharm. Sci. 81, 309\u2013312 (1992).","journal-title":"J. Pharm. Sci."},{"key":"41426_CR38","unstructured":"Gary, L., Horowitz, M. D. CLSI C28-A3: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline, Third Edition, C28A3E. vol. 28 (Clinical and Laboratory Standards Institute, 2010)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41426-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41426-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41426-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T01:08:42Z","timestamp":1700442522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41426-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["41426"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-41426-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14172"}}